United Therapeutics Corporation (UTHR): Price and Financial Metrics
GET POWR RATINGS... FREE!
UTHR POWR Grades
- UTHR scores best on the Value dimension, with a Value rank ahead of 92.69% of US stocks.
- UTHR's strongest trending metric is Growth; it's been moving down over the last 179 days.
- UTHR's current lowest rank is in the Momentum metric (where it is better than 25.17% of US stocks).
UTHR Stock Summary
- UTHR has a higher market value than 84.33% of US stocks; more precisely, its current market capitalization is $9,530,202,685.
- With a price/sales ratio of 5.33, UNITED THERAPEUTICS CORP has a higher such ratio than 79.8% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.3 for UNITED THERAPEUTICS CORP; that's greater than it is for merely 17.87% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to UNITED THERAPEUTICS CORP are OCUL, MRAM, GH, CRMD, and CODX.
- Visit UTHR's SEC page to see the company's official filings. To visit the company's web site, go to www.unither.com.
UTHR Valuation Summary
- In comparison to the median Healthcare stock, UTHR's EV/EBIT ratio is 43.75% higher, now standing at 11.5.
- UTHR's price/earnings ratio has moved up 28.2 over the prior 243 months.
Below are key valuation metrics over time for UTHR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| UTHR | 2022-09-23 | 5.3 | 2.2 | 15.0 | 11.5 |
| UTHR | 2022-09-22 | 5.3 | 2.2 | 15.0 | 11.5 |
| UTHR | 2022-09-21 | 5.2 | 2.2 | 14.8 | 11.4 |
| UTHR | 2022-09-20 | 5.3 | 2.2 | 14.9 | 11.4 |
| UTHR | 2022-09-19 | 5.5 | 2.3 | 15.6 | 12.0 |
| UTHR | 2022-09-16 | 5.6 | 2.3 | 15.7 | 12.0 |
UTHR Growth Metrics
- Its 4 year revenue growth rate is now at -9.54%.
- Its year over year price growth rate is now at -5.95%.
- Its 2 year cash and equivalents growth rate is now at -7.07%.
The table below shows UTHR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 1,788.7 | 775.9 | 630.8 |
| 2022-03-31 | 1,768.3 | 797.1 | 687.4 |
| 2021-12-31 | 1,685.5 | 598.2 | 475.8 |
| 2021-09-30 | 1,655.2 | 549.8 | 462.4 |
| 2021-06-30 | 1,590.6 | 615.1 | 470.9 |
| 2021-03-31 | 1,506.1 | 630.9 | 405.4 |
UTHR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- UTHR has a Quality Grade of A, ranking ahead of 95.85% of graded US stocks.
- UTHR's asset turnover comes in at 0.344 -- ranking 133rd of 681 Pharmaceutical Products stocks.
- NEOG, AMGN, and AERI are the stocks whose asset turnover ratios are most correlated with UTHR.
The table below shows UTHR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.344 | 0.925 | 0.142 |
| 2021-03-31 | 0.337 | 0.928 | 0.126 |
| 2020-12-31 | 0.344 | 0.927 | 0.167 |
| 2020-09-30 | 0.340 | 0.928 | 0.165 |
| 2020-06-30 | 0.354 | 0.922 | 0.158 |
| 2020-03-31 | 0.364 | 0.922 | 0.199 |
UTHR Price Target
For more insight on analysts targets of UTHR, see our UTHR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $231.89 | Average Broker Recommendation | 1.35 (Strong Buy) |
UTHR Stock Price Chart Interactive Chart >
UTHR Price/Volume Stats
| Current price | $215.62 | 52-week high | $245.48 |
| Prev. close | $213.93 | 52-week low | $158.38 |
| Day low | $212.56 | Volume | 376,500 |
| Day high | $217.31 | Avg. volume | 449,110 |
| 50-day MA | $219.39 | Dividend yield | N/A |
| 200-day MA | $206.28 | Market Cap | 9.81B |
United Therapeutics Corporation (UTHR) Company Bio
United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.
Latest UTHR News From Around the Web
Below are the latest news stories about UNITED THERAPEUTICS CORP that investors may wish to consider to help them evaluate UTHR as an investment opportunity.
Quant Billionaire Jim Simons Loves These 10 Defensive StocksIn this article, we discuss 10 defensive stocks that quant billionaire Jim Simons loves. If you want to read about some more stocks in the Simons portfolio, go directly to Quant Billionaire Jim Simons Loves These 5 Defensive Stocks. James Simons, the founder of New York-based Renaissance Technologies, manages an equity portfolio worth more than […] |
United Therapeutics Stops Late-Stage Tyvaso Study In Lung DiseaseUnited Therapeutics Corp (NASDAQ: UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with chronic obstructive pulmonary disease. The company terminated the study based on a recommendation of the study's independent Data Safety Monitoring Committee (DSMC), following a routine safety and efficacy analysis conducted by the DSMC. The company will review the study's available data and plan to share the results with |
Wedbush Initiates a Buy Rating on United Therapeutics (UTHR)In a report released today, Andreas Argyrides from Wedbush initiated coverage with a Buy rating on United Therapeutics (UTHR - Research Report) and a price target of $263.00. The company's shares closed last Friday at $218.11.According to TipRanks, Argyrides is an analyst with an average return of -14.8% and a 21.88% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, RegenXBio, and Albireo Pharma.The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $253.00 average price target. |
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit ReportSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 12, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance (ESG) priorities. Contained within the report is the company’s inaugural public benefit report, detailing United Therapeut |
3D Systems Announces Formation of New Biotech Company, Systemic Bio™, to Accelerate Drug Discovery and Developmenth-VIOS2 h-VIOS2 containing two perfused vascularized hydrogels. Within this chip’s footprint, any vasculature can be created. Taci Pereira Taci Pereira named CEO of Systemic Bio. New company will leverage 3D Systems’ recent breakthroughs in bioprinting of vascularized human organs and tissues to accelerate new drug development, reduce costs, and ultimately reduce or eliminate the need for animal testingUnique bioprinted organ-on-a-chip platform, h-VIOS™, created using hydrogels to produce comple |
UTHR Price Returns
| 1-mo | N/A |
| 3-mo | -10.23% |
| 6-mo | 13.92% |
| 1-year | 14.24% |
| 3-year | 172.28% |
| 5-year | 74.07% |
| YTD | -0.21% |
| 2021 | 42.35% |
| 2020 | 72.33% |
| 2019 | -19.12% |
| 2018 | -26.39% |
| 2017 | 3.15% |
Continue Researching UTHR
Want to see what other sources are saying about UNITED THERAPEUTICS Corp's financials and stock price? Try the links below:UNITED THERAPEUTICS Corp (UTHR) Stock Price | Nasdaq
UNITED THERAPEUTICS Corp (UTHR) Stock Quote, History and News - Yahoo Finance
UNITED THERAPEUTICS Corp (UTHR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...